BNTX
BioNTech SE
NASDAQ · Healthcare · Biotechnology · DE
$90.70
+4.35%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.4B | 2.8B | 2.8B | 3.8B | 17.3B |
| Cost of Revenue | 726.3M | 616.5M | 541.3M | 599.8M | 3.0B |
| Gross Profit | 1.7B | 2.1B | 2.2B | 3.2B | 14.3B |
| Operating Expenses | |||||
| R&D Expense | 2.4B | 2.0B | 2.3B | 1.8B | 1.5B |
| SG&A Expense | 818.8M | 698.2M | 599.0M | 557.7M | 541.2M |
| General & Admin Expense | 658.2M | 588.2M | 531.1M | 495.0M | 481.7M |
| Selling & Marketing Expense | 160.6M | 110.0M | 67.9M | 62.7M | 59.5M |
| Other Expenses | 228.4M | 44.0M | 670.9M | 188.0M | (405.3M) |
| Total Operating Expenses | 3.4B | 2.8B | 3.5B | 2.5B | 1.7B |
| Cost and Expenses | 4.1B | 3.4B | 4.1B | 3.1B | 4.7B |
| Operating Income (EBIT) | (1.7B) | (623.9M) | (1.3B) | 690.4M | 12.6B |
| Non-Operating | |||||
| Interest Income | 525.5M | 252.2M | — | 351.3M | 47.4M |
| Interest Expense | 26.7M | 13.6M | 13.2M | 7.8M | 15.8M |
| Net Interest Income | 498.7M | 238.6M | (13.2M) | 343.5M | 31.5M |
| Other Non-Op Income/Expense | 286.3M | (385.5M) | 636.6M | 495.7M | 311.4M |
| Non-Operating Income (excl Interest) | (313.0M) | 371.8M | (649.2M) | (503.6M) | (330.3M) |
| EBT (Pre-Tax Income) | (1.4B) | (1.0B) | (677.7M) | 1.2B | 13.0B |
| Income Tax Expense | 39.7M | 81.9M | (12.4M) | 255.8M | 3.5B |
| Bottom Line | |||||
| Net Income | (1.5B) | (1.1B) | (665.3M) | 930.3M | 9.4B |
| Earnings from Cont. Ops | (1.5B) | (1.1B) | (665.3M) | 930.3M | 9.4B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (1.5B) | (1.1B) | (665.3M) | 930.3M | 9.4B |
| Per Share | |||||
| Basic EPS | ($5.87) | ($4.51) | ($2.77) | $3.87 | $38.08 |
| Diluted EPS | ($5.88) | ($4.51) | ($2.77) | $3.83 | $37.09 |
| Revenue Per Share | $9.69 | $11.41 | $11.44 | $15.87 | $71.15 |
| Shares | |||||
| Basic Shares Outstanding | 249.0M | 241.7M | 240.4M | 240.6M | 243.3M |
| Diluted Shares Outstanding | 253.0M | 241.7M | 240.4M | 242.7M | 249.8M |
| Profitability Metrics | |||||
| EBITDA | (527.8M) | (628.0M) | (367.1M) | 1.4B | 13.1B |
| D&A | 884.9M | 367.7M | 298.0M | 183.4M | 123.3M |
| EBIT | (1.4B) | (995.7M) | (665.1M) | 1.2B | 13.0B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026